Prana Biotechnology Ltd.'s dreams of becoming a late-stage drug development company in 2005 suffered a blow Monday with the company's decision to cancel an upcoming Phase II/III trial of PBT1, a disease-modifying compound for Alzheimer's disease, due to manufacturing toxicity issues. (BioWorld International) Read More
